Publications by authors named "Peter M Mross"
Background: Assessment of quality of life (QoL) has become an important indicator for chronic neurological diseases. While these conditions often limit personal independence and autonomy, they are also associated with treatment-related problems and reduced life expectancy. Epilepsy has a tremendous impact on the QoL of patients and their families, which is often underestimated by practitioners.
View Article and Find Full Text PDFObjective: Functional seizures (FS) or psychogenic, non-epileptic seizures (PNES) are episodic alterations of behaviour with similar semiology to epileptic seizures but which are not caused by epileptic brain activity. Epilepsy patients show a high risk in developing FS; therefore, the purpose of this study is to examine morphometric correlates in patients with FS as well as in epilepsy patients with FS by comparing them separately to healthy controls (HC).
Methods: Twenty-one clinical three-dimensional (3D) T1-magnetic resonance imaging (MRI) scans of patients with FS (FS group) and 15 patients with FS and epilepsy (EFS group) were retrospectively compared with one control group of 21 age- and gender-matched HC.
Article Synopsis
- Memory complaints are infrequent in patients experiencing their first seizure and do not correlate with actual memory performance or the diagnosis of epilepsy.
- The study involved 61 patients who completed memory tasks and questionnaires regarding their memory and mood following their first seizure, revealing that only 10% reported memory complaints.
- The findings suggest that unlike chronic epilepsy cases, where memory issues are more common, memory complaints at the onset of epilepsy are rare, underscoring the importance of early neurological and psychological support for newly diagnosed patients.
The Flynn effect describes an increase in intelligence quotient (IQ) in the general population of about 3 points per decade. While this effect is well established in healthy individuals, research exploring the link to brain pathologies is scarce. We investigated the Flynn effect in a German sample of 203 patients with epilepsy with left, right, and bilateral lesions.
View Article and Find Full Text PDFObjectives: Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting.
Design: Retrospective, observational multicentre study.
Objectives: To assess first clinical experiences with brivaracetam (BRV) in the treatment of epilepsies.
Methods: Data on patients treated with BRV from February to December 2016 and with at least one clinical follow-up were collected from electronic patient records. Data on safety and efficacy were evaluated retrospectively.